Foundayo is a non-peptide GLP-1 receptor agonist that has been FDA-approved for weight loss as a once-daily pill
Expert perspective: healthcare researchers who track telehealth weight-loss platforms generally note that companies employing board-certified obesity medicine physicians , rather than general practitioners moonlighting in telehealth, tend to produce more consistent and safer outcomes
The press conference later resumed, with Trump saying one of the representatives from one of the companies got a "little bit lightheaded" and "went down" but is "fine."
Im sure in 30 years, people will look back on this low point of self-medication with products that are both dangerous and ineffective. Peterss main peptide of choice is retatrutide , which supposedly has an Ozempic-like effect on GLP-1, GIP, and glucagon receptors, controlling his appetite
Thank you for sharing this alarming but necessary research Ziyad
This is due to the potential risk of thyroid cancer associated with Mounjaro